Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies.
Noto FK, Sangodkar J, Adedeji BT, Moody S, McClain CB, Tong M, Ostertag E, Crawford J, Gao X, Hurst L, O'Connor CM, Hanson EN, Izadmehr S, Tohmé R, Narla J, LeSueur K, Bhattacharya K, Rupani A, Tayeh MK, Innis JW, Galsky MD, Evers BM, DiFeo A, Narla G, Jamling TY. Noto FK, et al. Among authors: sangodkar j. PLoS One. 2020 Oct 7;15(10):e0240169. doi: 10.1371/journal.pone.0240169. eCollection 2020. PLoS One. 2020. PMID: 33027304 Free PMC article.
Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts.
Noto FK, Adjan-Steffey V, Tong M, Ravichandran K, Zhang W, Arey A, McClain CB, Ostertag E, Mazhar S, Sangodkar J, DiFeo A, Crawford J, Narla G, Jamling TY. Noto FK, et al. Among authors: sangodkar j. Mol Cancer Ther. 2018 Nov;17(11):2481-2489. doi: 10.1158/1535-7163.MCT-18-0156. Epub 2018 Sep 11. Mol Cancer Ther. 2018. PMID: 30206106 Free PMC article.
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
Farrington CC, Yuan E, Mazhar S, Izadmehr S, Hurst L, Allen-Petersen BL, Janghorban M, Chung E, Wolczanski G, Galsky M, Sears R, Sangodkar J, Narla G. Farrington CC, et al. Among authors: sangodkar j. J Biol Chem. 2020 Jan 17;295(3):757-770. doi: 10.1074/jbc.RA119.011443. Epub 2019 Dec 10. J Biol Chem. 2020. PMID: 31822503 Free PMC article.
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.
Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, Borczuk AC, Gokulrangan G, Wang L, Svenson E, Farrington CC, Yuan E, Avelar RA, Stachnik A, Smith B, Gidwani V, Giannini HM, McQuaid D, McClinch K, Wang Z, Levine AC, Sears RC, Chen EY, Duan Q, Datt M, Haider S, Ma'ayan A, DiFeo A, Sharma N, Galsky MD, Brautigan DL, Ioannou YA, Xu W, Chance MR, Ohlmeyer M, Narla G. Sangodkar J, et al. J Clin Invest. 2017 Jun 1;127(6):2081-2090. doi: 10.1172/JCI89548. Epub 2017 May 15. J Clin Invest. 2017. PMID: 28504649 Free PMC article.
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.
Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, Burstein D, Zhang D, Politi K, Difeo A, Narla G. Sangodkar J, et al. J Clin Invest. 2012 Jul;122(7):2637-51. doi: 10.1172/JCI62058. Epub 2012 Jun 1. J Clin Invest. 2012. PMID: 22653055 Free PMC article.
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
O'Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, Bryson B, Tokala E, Taylor SE, Upadhyay A, Sangodkar J, Gingras AC, Westermarck J, Xu W, DiFeo A, Brautigan DL, Haider S, Jackson M, Narla G. O'Connor CM, et al. Among authors: sangodkar j. Oncogene. 2020 Jan;39(3):703-717. doi: 10.1038/s41388-019-1012-2. Epub 2019 Sep 20. Oncogene. 2020. PMID: 31541192 Free PMC article.
29 results